期刊文献+

IP与CAV二线方案治疗复发小细胞肺癌的疗效比较 被引量:2

Clinical efficacy of CPT-11 plus cisplatin and cyclophosphamide doxorubicin and vincristine in treatment of small cell lung cancer
下载PDF
导出
摘要 目的比较IP(伊立替康+顺铂)与CAV(环磷酰胺+阿霉素+长春新碱)作为二线方案治疗复发小细胞肺癌(SCLC)的疗效和不良反应。方法复发SCLC患者68例随机分为2组,34例给予IP方案化疗:盐酸依立替康60 mg/m^2静脉滴注,第1、8、15天;顺铂25 mg/m^2静脉滴注,第1~3天,28 d为1周期。另34例给予CAV方案化疗;环磷酰胺800 mg/m^2静脉注射,第1天,阿霉素50 mg/m^2静脉注射,第1天,长春新碱1.4 mg/m^2静脉注射,第1天,21 d为1周期,每例患者至少完成2周期化疗后评价疗效。结果 IP组总有效率41.2%高于CAV组总有效率26.4%(P<0.05)。2组生存时间比较差异无统计学意义(P>0.05)。不良反应主要为血液学毒性及消化道毒性,Ⅳ级毒性比较差异无统计学意义(P>0.05)。结论 IP作为二线方案治疗复发SCLC疗效优于CAV,两者不良反应均可耐受。 Objective To compare the clinical efficacy and adverse reactions of CPT-11 plus cis platin(IP) and cyclophosphamide doxorubicin and vincristine(CAV) in second line treatment of small cell lung cancer(SCLC).Methods 68 patients with SCLC who had relapsed at least 60 day after completion of first line therapy were randomly divided into IP group (34 patients) and CAV group(34 patients).Those in IP group were given CPT-11 60 mg/m^2 on the 1st day,8th day and 15th day,coupled with addition of cis platin 25 mg/m^2 from the 1st to 3rd day.A chemotherapeutic cycle of 28 days was repeated at least once in each case;and those in the CAV group were infused cyclophosphamide 800 mg/m^2 coupled with addition of doxorubicin 50 mg/m^2 and vincristine 1.4 mg/m^2 on day 1 every 21 days.All patients after 2 cycles of chemotherapy were collected two sets of clinical data and clinical assessment of efficacy and toxicity.Results The response rate of IP group was 41.2%,and that of CAV group was 26.4%,with significant difference(P 0.05 ).In the adverse effects of treatment, the main toxicity included the bone marrow suppression and gastrointestinal disturbance(P 0.05).Conclusion IP regimen has the prior effect than CAV regimen in second line treatment of SCLC owing to its better efficacy and equal toxicity,so IP regimen is firstly recommended in the chemotherapy for recurrent SCLC.
作者 于滨 苏智祥
出处 《疑难病杂志》 CAS 2013年第2期114-116,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 小细胞肺癌 化学疗法 伊立替康 Small cell lung cancer Chemotherapy Irinotecan
  • 相关文献

参考文献7

  • 1Jagasia MH,Langer CJ,Johson DH. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer:A multicenter phaseⅡstudy[J].Clinical Cancer Research,2001,(01):68-73.
  • 2Hirose T,Horichi N,Ohmori T. PhaseⅡstudy of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer[J].Lung Cancer,2003,(03):333-338.
  • 3Mascaux C,Paesmans M,Berghmans T. European Lung Cancer Working Party (ELCWP).A systematic review of the role of etoposide and cisplatin in the chemotherapy of small-cell lung cancer with methodology assessment and meta-analysis[J].Lung Cancer,2000,(01):23-36.
  • 4Sundstrom S,Bremnes RM,Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide,epirubicin,and vincristine regimen in small-cell lung cancer:results from a randomized phase III trial with 5 years' follow-up[J].Journal of Clinical Oncology,2002,(24):4665-4672.
  • 5Ettinger DS,Jotte R,Lorigan P. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer[J].Journal of Clinical Oncology,2010,(15):2598-2603.
  • 6燕小薇,胡伟国,许小涛,宋启斌.小细胞肺癌的靶向治疗进展[J].中国肿瘤,2009,18(8):657-659. 被引量:2
  • 7袁林秀.介入治疗小细胞肺癌35例分析[J].实用医技杂志,2007,14(8):967-968. 被引量:1

二级参考文献24

  • 1黄爱珠.化疗在小细胞肺癌综合治疗中的作用[J].川北医学院学报,1994,9(1):83-86. 被引量:1
  • 2苑静波,史金英,啜振华.中晚期肺癌的介入治疗与全身静脉化疗疗效观察[J].实用肿瘤杂志,2005,20(4):339-341. 被引量:14
  • 3张力克,王志康,王克诚.小细胞肺癌的综合治疗[J].河北医药,2006,28(6):516-517. 被引量:3
  • 4王宗林,周楠,谢晓阳,代新学,任超峰.支气管动脉灌注化疗治疗肺癌42例临床分析[J].实用癌症杂志,2006,21(3):286-287. 被引量:2
  • 5Chute JP, Chen T, Feigal E, et al. Twenty years of phase Ⅲ trials for patients with extensive-stage small-cell lung cancer: perceptible progress[J]. J Clin Oncol, 1999, 17(6) : 1794-1801.
  • 6Herbst RS,Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications[J]. J Clin Oncol, 2005, 23(14):3243-3256.
  • 7Sandler A SS,Dowlati A. A phase Ⅱ study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group [A]. Proc Am Soc Clin Oncol [C]. Chicago: ASCO, 2007. 400S.
  • 8Ready N DA,Wang XF.CALGB 30306: a phase Ⅱ study of cisplatin (C), Irinotecan (i) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) [A]. Proc Am Soc Clin Oncol [C]. Chicago: ASCO, 2007. 400S.
  • 9Hal Barton. Important drug warning regarding avastin (bevacizumab) [EB/OL]. http://www.gene.com/gene/products/ imformation/pdf/avastin_te_letter.pdf, 2007.
  • 10Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer[J].Cancer Res,2005,65(10):4389-4400.

共引文献1

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部